Table 2

Longitudinal analysis of HMGB1 levels in patients with antineutrophil cytoplasmic antibodies-associated vasculitis

Variable

Presentation

Early remissiona

Ongoing remission

Prior to relapse 1

Relapse 1

Prior to relapse 2

Relapse 2


HMGB1 (ng/ml)

2.35 (1.48 to 3.15)

1.69* (0.88 to 2.73)

2.21 (1.42 to 3.68)

2.59 (1.61 to 4.09)

2.56 (0.87 to 4.48)

3.65 (1.71 to 4.56)

2.77 (0.91 to 4.86)

Follow-up period (months)

0

3.0b (3.0 to 6.0)

11.0b (6.0 to 12.0)

2.0c (2.0 to 3.0)

20.0b (13.0 to 41.5)

2.0c (1.0 to 2.0)

44.0b (35.2 to 68.5)

BVAS

15.0 (12.0 to 23.5)

0

0

0

12.0 (5.5 to 13.5)

0

11.0 (5.7 to 15.7)

Number of patients

52

49

49

15

17

5

6


Data presented as median (interquartile range). BVAS, Birmingham Vasculitis Activity Score; HMGB1, high-mobility group box 1. aEarly remission indicates when remission was achieved following induction treatment. bMonths after presentation. cMonths prior to the relapse. *Significant P value for fluctuation in HMGB1 levels between presentation and early remission.

de Souza et al. Arthritis Research & Therapy 2013 15:R104   doi:10.1186/ar4284

Open Data